E-Cadherin Immunostaining in Equine Melanocytic Tumors.
Authors: Pimenta José, Pires Isabel, Prada Justina, Cotovio Mário
Journal: Animals : an open access journal from MDPI
Summary
# Editorial Summary: E-Cadherin Expression in Equine Melanocytic Tumors Equine melanomas behave remarkably differently from their human and small animal counterparts, remaining largely benign with minimal invasive or metastatic potential—a phenomenon that may be explained by differences in molecular tumour progression pathways. Researchers immunohistochemically evaluated E-cadherin expression in 72 equine melanocytic tumours (classified as benign or malignant) to determine whether epithelial-mesenchymal transition and associated loss of E-cadherin, well-documented mechanisms in other species' malignant melanomas, occur in horses. The study revealed an unexpected pattern: 69.4% of all tumours showed elevated E-cadherin immunolabelling, with 70.7% of malignant melanomas retaining high expression—contrasting sharply with the characteristic E-cadherin downregulation seen in invasive human and small animal melanomas, and no meaningful difference in expression between benign and malignant equine tumours. This preserved E-cadherin expression may constitute a protective mechanism contributing to the indolent nature of equine melanoma, suggesting that the biological behaviour of these tumours is governed by distinct genetic pathways rather than the invasion-promoting mechanisms that drive malignancy in other species. For practitioners, these findings support a more conservative approach to equine melanoma management and indicate that histological classification alone may not reliably predict biological behaviour, though further study of alternative molecular markers is warranted.
Read the full abstract on PubMed
Practical Takeaways
- •Equine melanocytic tumors behave fundamentally differently from melanomas in humans and small animals, with preserved E-cadherin expression correlating with their generally benign behavior and low metastatic potential
- •The absence of typical epithelial-mesenchymal transition markers in equine melanomas suggests that standard prognostic indicators used in other species may not be applicable to equine cases
- •E-cadherin immunostaining alone cannot distinguish between benign and malignant equine melanomas, so additional clinicopathological assessment remains necessary for prognosis and treatment planning
Key Findings
- •69.4% of equine melanocytic tumors showed raised E-cadherin immunolabeling, contrasting with the typical loss of E-cadherin expression seen in melanomas of other species
- •70.7% of malignant equine melanomas retained high E-cadherin expression, unlike human and small animal melanomas which show loss of expression during progression
- •No significant differences in E-cadherin immunostaining were found between benign and malignant equine melanomas
- •High E-cadherin expression may explain the characteristically low invasiveness and rare metastatic behavior of equine melanocytic tumors compared to other species